
Opinion|Videos|April 11, 2025
Personalizing Treatment in Alopecia Areata
Author(s)Arash Mostaghimi, MD, MPH, Brett King, MD, PhD
A panelist discusses how determining whether a Janus kinase (JAK) inhibitor is the appropriate treatment for alopecia areata patients, which involves carefully evaluating disease severity, duration, and extent of hair loss, considering previous treatment failures, assessing patient comorbidities and risk factors, reviewing comprehensive laboratory results, discussing potential benefits vs risks of JAK therapy, and establishing realistic expectations about treatment timeline and potential adverse effects.
Advertisement
Episodes in this series

How do you decide whether a JAK inhibitor is an appropriate treatment option for a patient?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI
2
Skin of Color Savvy: Mentorship in Dermatology—Building the Next Generation of Leaders
3
WAO Delphi Consensus Endorses ED05-Based Allergen Labelling
4
Understanding the B-Cell Pathway in IgA Nephropathy, With Samir Parikh, MD
5







































































